| Myasthenia Gravis, Generalized
Ultomiris vs Uplinza
Side-by-side clinical, coverage, and cost comparison for myasthenia gravis, generalized.Deep comparison between: Ultomiris vs Uplizna with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsUplizna has a higher rate of injection site reactions vs Ultomiris based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Uplizna but not Ultomiris, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Ultomiris
Uplizna
At A Glance
IV infusion
Every 4-8 weeks
C5 complement inhibitor
IV infusion
Every 6 months
CD19-directed cytolytic antibody
Indications
- Paroxysmal nocturnal hemoglobinuria
- Atypical Hemolytic Uremic Syndrome
- Myasthenia Gravis, Generalized
- Neuromyelitis Optica
- Neuromyelitis Optica
- Immunoglobulin G4-Related Disease
- Myasthenia Gravis, Generalized
Dosing
Paroxysmal nocturnal hemoglobinuria, Atypical Hemolytic Uremic Syndrome (5 to <40 kg) Weight-based IV loading dose (600-1,200 mg), followed by weight-based maintenance dose every 4 weeks (5 to <20 kg) or every 8 weeks (20 to <40 kg), starting 2 weeks after loading dose.
Paroxysmal nocturnal hemoglobinuria, Atypical Hemolytic Uremic Syndrome, Myasthenia Gravis, Generalized, Neuromyelitis Optica (>=40 kg) Weight-based IV loading dose (2,400-3,000 mg), followed by weight-based maintenance dose (3,000-3,600 mg) every 8 weeks, starting 2 weeks after loading dose.
Neuromyelitis Optica, Immunoglobulin G4-Related Disease, Myasthenia Gravis, Generalized Initial dose: 300 mg IV infusion, followed 2 weeks later by a second 300 mg IV infusion; subsequent doses: 300 mg IV infusion every 6 months starting 6 months from first infusion; premedicate with a corticosteroid (methylprednisolone 80-125 mg IV), antihistamine (diphenhydramine 25-50 mg oral), and antipyretic (acetaminophen 500-650 mg oral) before each infusion; dilute in 250 mL 0.9% Sodium Chloride and infuse over approximately 90 minutes.
Contraindications
- Unresolved serious Neisseria meningitidis infection
- History of life-threatening infusion reaction to inebilizumab-cdon or any excipient
- Active hepatitis B infection (confirmed by positive HBsAg and anti-HBV tests)
- Active or untreated latent tuberculosis
Adverse Reactions
Most common (>=10%) Upper respiratory tract infection, headache, diarrhea, nausea, vomiting, hypertension, pyrexia, back pain, arthralgia, COVID-19
Serious Meningococcal infections, other infections (including fatal COVID-19 pneumonia and sepsis), infusion-related reactions
Postmarketing Anaphylaxis, cholestatic or mixed pattern liver injury with increased serum liver enzymes and bilirubin
Most common (>=10%) Urinary tract infection, nasopharyngitis, infusion-related reaction, arthralgia, headache, lymphopenia
Serious Infusion reactions, infections, reduction in immunoglobulins
Pharmacology
Ravulizumab-cwvz is a terminal complement inhibitor that specifically binds complement protein C5 with high affinity, preventing its cleavage to C5a (proinflammatory anaphylatoxin) and C5b (initiating subunit of the membrane attack complex), thereby inhibiting MAC formation and terminal complement-mediated tissue damage in PNH, aHUS, gMG, and NMOSD.
CD19-directed humanized afucosylated IgG1 monoclonal antibody; binds CD19 on pre-B and mature B lymphocytes and induces antibody-dependent cellular cytolysis, depleting B-cell counts within 8 days of infusion.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ultomiris
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (0/12)
Uplizna
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (9/12)
UnitedHealthcare
Ultomiris
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Uplizna
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Ultomiris
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Uplizna
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Ultomiris.
$0
Amgen By Your Side Copay Assistance Program: UpliznaCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
UltomirisView full Ultomiris profile
UpliznaView full Uplizna profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.